Telaprevir - Benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) according to § 35a of the Social Security Code Book v (dossier evaluation): Opinion of the Board of Directors of the German Society for Digestive and Metabolic Diseases (DGVS);Telaprevir-Nutzenbewertung des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) gemäß 35a SGB V (Dossierbewertung): Stellungnahme des Vorstands der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)

Zeitschrift fur Gastroenterologie

Volumn 50, Issue 3, 2012, Pages 271-272

  Dignaß, Axel ^a   Galle, Peter ^a   Hochberger, Jürgen ^a   Layer, Peter ^a   Lerch, Markus ^a   Wehrmann, Till ^a   Zeuzem, Stefan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

DRUG EFFICACY; HEALTH CARE ORGANIZATION; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; RELAPSE; RISK REDUCTION; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; GASTROENTEROLOGY; GERMANY; HEPATITIS C; HUMANS; OLIGOPEPTIDES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84857840206     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1299319     Document Type: Short Survey

References (0)